DAFNA Capital Management LLC historic quarter change: USA Stocks, Sold out
In share positions in stocks (listed in the US), over 23 quarters from 2013-06-30 to 2026-06-30, DAFNA Capital Management LLC opened 109 positions, added to 185, reduced 215 and sold out of 73.
- Q2 2026: Stock DAWN; Country of operation United States; Class COM; Shares before 978,463.
- Q2 2026: Stock TNDM; Country of operation United States; Class COM NEW; Shares before 355,208.
- Q2 2026: Stock KALV; Country of operation United States; Class COM; Shares before 267,402.
- Q2 2026: Stock FULC; Country of operation United States; Class COM; Shares before 205,000.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1389933), 23 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-17); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-15); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-12); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-13); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-14); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-17); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-02-14); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-11-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2006-12-31. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q2 2026 | DAWN
DAY ONE BIOPHARMACEUTICALS I | United States | COM | 978,463 | 0 | -978,463 | $20,978,247 | $0 | -$20,978,247 | 2026-08-14 |
|---|
| Q2 2026 | TNDM
TANDEM DIABETES CARE INC | United States | COM NEW | 355,208 | 0 | -355,208 | $6,809,337 | $0 | -$6,809,337 | 2026-08-14 |
|---|
| Q2 2026 | KALV
KALVISTA PHARMACEUTICALS INC | United States | COM | 267,402 | 0 | -267,402 | $5,382,802 | $0 | -$5,382,802 | 2026-08-14 |
|---|
| Q2 2026 | FULC
FULCRUM THERAPEUTICS INC | United States | COM | 205,000 | 0 | -205,000 | $1,572,350 | $0 | -$1,572,350 | 2026-08-14 |
|---|
| Q2 2026 | ORIC
ORIC PHARMACEUTICALS INC | United States | COM | 98,724 | 0 | -98,724 | $945,460 | $0 | -$945,460 | 2026-08-14 |
|---|
| Q2 2026 | NAMS
NEWAMSTERDAM PHARMA CO | | ORDINARY SHARES | 20,000 | 0 | -20,000 | $640,200 | $0 | -$640,200 | 2026-08-14 |
|---|
| Q2 2026 | KPTI
KARYOPHARM THERAPEUTICS INC | United States | COM NEW | 45,800 | 0 | -45,800 | $255,106 | $0 | -$255,106 | 2026-08-14 |
|---|
| Q2 2026 | NMRA
NEUMORA THERAPEUTICS INC | United States | COM | 70,000 | 0 | -70,000 | $136,500 | $0 | -$136,500 | 2026-08-14 |
|---|
| Q1 2026 | ATXS
ASTRIA THERAPEUTICS INC | United States | COM | 304,775 | 0 | -304,775 | $3,989,505 | $0 | -$3,989,505 | 2026-05-15 |
|---|
| Q1 2026 | ERAS
ERASCA INC | United States | COM | 254,436 | 0 | -254,436 | $946,502 | $0 | -$946,502 | 2026-05-15 |
|---|
| Q1 2026 | CATX
PERSPECTIVE THERAPEUTICS INC | United States | COM NEW | 50,000 | 0 | -50,000 | $137,500 | $0 | -$137,500 | 2026-05-15 |
|---|
| Q4 2025 | MRUS
MERUS BV | | COM | 220,451 | 0 | -220,451 | $20,755,462 | $0 | -$20,755,462 | 2026-02-17 |
|---|
| Q4 2025 | SLNO
SOLENO THERAPEUTICS INC | United States | COM | 53,000 | 0 | -53,000 | $3,582,800 | $0 | -$3,582,800 | 2026-02-17 |
|---|
| Q4 2025 | CMPX
COMPASS THERAPEUTICS INC | United States | COM | 946,661 | 0 | -946,661 | $3,313,314 | $0 | -$3,313,314 | 2026-02-17 |
|---|
| Q4 2025 | KRRO
KORRO BIO INC | United States | COM | 60,804 | 0 | -60,804 | $2,911,904 | $0 | -$2,911,904 | 2026-02-17 |
|---|
| Q4 2025 | KROS
KEROS THERAPEUTICS INC | United States | COM | 80,716 | 0 | -80,716 | $1,276,927 | $0 | -$1,276,927 | 2026-02-17 |
|---|
| Q4 2025 | BDTX
BLACK DIAMOND THERAPEUTICS I | United States | COM | 307,070 | 0 | -307,070 | $1,163,795 | $0 | -$1,163,795 | 2026-02-17 |
|---|
| Q4 2025 | URGN
UROGEN PHARMA LTD | | COM | 27,515 | 0 | -27,515 | $548,924 | $0 | -$548,924 | 2026-02-17 |
|---|
| Q4 2025 | APRE
APREA THERAPEUTICS INC | United States | COM NEW | 137,174 | 0 | -137,174 | $202,332 | $0 | -$202,332 | 2026-02-17 |
|---|
| Q3 2025 | ITOS
ITEOS THERAPEUTICS INC | United States | COM | 140,847 | 0 | -140,847 | $1,404,245 | $0 | -$1,404,245 | 2025-11-14 |
|---|
| Q3 2025 | GOSS
GOSSAMER BIO INC | United States | COM | 849,921 | 0 | -849,921 | $1,045,403 | $0 | -$1,045,403 | 2025-11-14 |
|---|
| Q3 2025 | PVLA
PALVELLA THERAPEUTICS INC | United States | COM | 43,348 | 0 | -43,348 | $977,064 | $0 | -$977,064 | 2025-11-14 |
|---|
| Q3 2025 | PRCT
PROCEPT BIOROBOTICS CORP | United States | COM | 3,000 | 0 | -3,000 | $172,800 | $0 | -$172,800 | 2025-11-14 |
|---|
| Q3 2025 | IFRX
INFLARX NV | | COM | 200,000 | 0 | -200,000 | $158,000 | $0 | -$158,000 | 2025-11-14 |
|---|
| Q2 2025 | SPRY
ARS PHARMACEUTICALS INC | United States | COM | 95,290 | 0 | -95,290 | $1,198,748 | $0 | -$1,198,748 | 2025-08-14 |
|---|
| Q2 2025 | LCTX
LINEAGE CELL THERAPEUTICS IN | United States | COM | 2,511,374 | 0 | -2,511,374 | $1,134,136 | $0 | -$1,134,136 | 2025-08-14 |
|---|
| Q2 2025 | TSHA
TAYSHA GENE THERAPIES INC | United States | COM SHS | 522,500 | 0 | -522,500 | $726,275 | $0 | -$726,275 | 2025-08-14 |
|---|
| Q2 2025 | CRDF
CARDIFF ONCOLOGY INC | United States | COM | 150,000 | 0 | -150,000 | $471,000 | $0 | -$471,000 | 2025-08-14 |
|---|
| Q2 2025 | SPRO
SPERO THERAPEUTICS INC | United States | COM | 125,000 | 0 | -125,000 | $90,000 | $0 | -$90,000 | 2025-08-14 |
|---|
| Q2 2025 | TNYA
TENAYA THERAPEUTICS INC | United States | COM | 47,319 | 0 | -47,319 | $26,977 | $0 | -$26,977 | 2025-08-14 |
|---|
| Q1 2025 | VIR
VIR BIOTECHNOLOGY INC | United States | COM | 100,000 | 0 | -100,000 | $734,000 | $0 | -$734,000 | 2025-05-15 |
|---|
| Q1 2025 | ACRV
ACRIVON THERAPEUTICS INC | United States | COMMON STOCK | 112,414 | 0 | -112,414 | $676,732 | $0 | -$676,732 | 2025-05-15 |
|---|
| Q1 2025 | MASI
MASIMO CORP | United States | COM | 3,000 | 0 | -3,000 | $495,900 | $0 | -$495,900 | 2025-05-15 |
|---|
| Q1 2025 | CATX
PERSPECTIVE THERAPEUTICS INC | United States | COM NEW | 130,169 | 0 | -130,169 | $415,239 | $0 | -$415,239 | 2025-05-15 |
|---|
| Q1 2025 | CMPX
COMPASS THERAPEUTICS INC | United States | COM | 158,394 | 0 | -158,394 | $229,671 | $0 | -$229,671 | 2025-05-15 |
|---|
| Q4 2024 | NYXH
NYXOAH S A | | SHS | 108,108 | 0 | -108,108 | $1,032,431 | $0 | -$1,032,431 | 2025-02-14 |
|---|
| Q4 2024 | GRAL
GRAIL INC | United States | COM | 48,800 | 0 | -48,800 | $671,488 | $0 | -$671,488 | 2025-02-14 |
|---|
| Q4 2024 | TRML
TOURMALINE BIO INC | United States | COM | 19,110 | 0 | -19,110 | $491,318 | $0 | -$491,318 | 2025-02-14 |
|---|
| Q4 2024 | VSTM
VERASTEM INC | United States | COM NEW | 127,700 | 0 | -127,700 | $381,823 | $0 | -$381,823 | 2025-02-14 |
|---|
| Q4 2024 | ANRO
ALTO NEUROSCIENCE INC | United States | COM SHS | 26,786 | 0 | -26,786 | $306,432 | $0 | -$306,432 | 2025-02-14 |
|---|
| Q4 2024 | STIM
NEURONETICS INC | United States | COM | 313,717 | 0 | -313,717 | $238,362 | $0 | -$238,362 | 2025-02-14 |
|---|
| Q3 2024 | PRCT
PROCEPT BIOROBOTICS CORP | United States | COM | 13,994 | 0 | -13,994 | $854,893 | $0 | -$854,893 | 2024-11-14 |
|---|
| Q3 2024 | SYRS
SYROS PHARMACEUTICALS INC | United States | COM NEW | 135,850 | 0 | -135,850 | $700,986 | $0 | -$700,986 | 2024-11-14 |
|---|
| Q3 2024 | TERN
TERNS PHARMACEUTICALS INC | United States | COM | 86,000 | 0 | -86,000 | $585,660 | $0 | -$585,660 | 2024-11-14 |
|---|
| Q3 2024 | ORIC
ORIC PHARMACEUTICALS INC | United States | COM | 36,000 | 0 | -36,000 | $254,520 | $0 | -$254,520 | 2024-11-14 |
|---|
| Q1 2024 | AMLX
AMYLYX PHARMACEUTICALS INC | United States | COM | 122,547 | 0 | -122,547 | $1,803,892 | $0 | -$1,803,892 | 2024-05-15 |
|---|
| Q1 2024 | MGNX
MACROGENICS INC | United States | COM | 152,250 | 0 | -152,250 | $1,464,645 | $0 | -$1,464,645 | 2024-05-15 |
|---|
| Q1 2024 | CGEM
CULLINAN ONCOLOGY INC | United States | COM | 127,284 | 0 | -127,284 | $1,297,024 | $0 | -$1,297,024 | 2024-05-15 |
|---|
| Q1 2024 | ORIC
ORIC PHARMACEUTICALS INC | United States | COM | 72,797 | 0 | -72,797 | $669,732 | $0 | -$669,732 | 2024-05-15 |
|---|
| Q1 2024 | VTGN
VISTAGEN THERAPEUTICS INC | United States | COM | 41,886 | 0 | -41,886 | $215,294 | $0 | -$215,294 | 2024-05-15 |
|---|
| Q3 2016 | ABBV
ABBVIE INC | United States | COM | 76,331 | 0 | -76,331 | $4,726,000 | $0 | -$4,726,000 | 2016-11-14 |
|---|
| Q3 2016 | STXS
STEREOTAXIS INC | United States | COM NEW | 1,372,862 | 0 | -1,372,862 | $1,345,000 | $0 | -$1,345,000 | 2016-11-14 |
|---|
| Q3 2016 | GERN
GERON CORP | United States | COM | 285,000 | 0 | -285,000 | $764,000 | $0 | -$764,000 | 2016-11-14 |
|---|
| Q3 2016 | ABUS
ARBUTUS BIOPHARMA CORP | | COM | 75,000 | 0 | -75,000 | $261,000 | $0 | -$261,000 | 2016-11-14 |
|---|
| Q3 2016 | AKBA
AKEBIA THERAPEUTICS INC | United States | COM | 24,700 | 0 | -24,700 | $185,000 | $0 | -$185,000 | 2016-11-14 |
|---|
| Q3 2016 | ALDX
ALDEYRA THERAPEUTICS INC | United States | COM | 2,499 | 0 | -2,499 | $14,000 | $0 | -$14,000 | 2016-11-14 |
|---|
| Q2 2016 | MNOV
MEDICINOVA INC | United States | COM NEW | 125,000 | 0 | -125,000 | $918,000 | $0 | -$918,000 | 2016-08-15 |
|---|
| Q2 2016 | CDNA
CAREDX INC | United States | COM | 136,047 | 0 | -136,047 | $675,000 | $0 | -$675,000 | 2016-08-15 |
|---|
| Q2 2016 | BCRX
BIOCRYST PHARMACEUTICALS INC | United States | COM | 149,642 | 0 | -149,642 | $423,000 | $0 | -$423,000 | 2016-08-15 |
|---|
| Q4 2015 | GILD
GILEAD SCIENCES INC | United States | COM | 5,700 | 0 | -5,700 | $560,000 | $0 | -$560,000 | 2016-02-12 |
|---|
| Q4 2015 | AMGN
AMGEN INC | United States | COM | 3,700 | 0 | -3,700 | $512,000 | $0 | -$512,000 | 2016-02-12 |
|---|
| Q2 2015 | ALDX
ALDEYRA THERAPEUTICS INC | United States | COM | 35,000 | 0 | -35,000 | $356,000 | $0 | -$356,000 | 2015-08-14 |
|---|
| Q2 2015 | FATE
FATE THERAPEUTICS INC | United States | COM | 20,190 | 0 | -20,190 | $99,000 | $0 | -$99,000 | 2015-08-14 |
|---|
| Q1 2015 | CDNA
CAREDX INC | United States | COM ADDED | 87,300 | 0 | -87,300 | $633,000 | $0 | -$633,000 | 2015-05-15 |
|---|
| Q1 2015 | BLFS
BIOLIFE SOLUTIONS INC | United States | COM NEW | 116,279 | 0 | -116,279 | $191,000 | $0 | -$191,000 | 2015-05-15 |
|---|
| Q4 2014 | NBIX
NEUROCRINE BIOSCIENCES INC | United States | COM | 66,141 | 0 | -66,141 | $1,036,000 | $0 | -$1,036,000 | 2015-02-17 |
|---|
| Q4 2014 | CDNA
CAREDX INC | United States | COM | 75,000 | 0 | -75,000 | $525,000 | $0 | -$525,000 | 2015-02-17 |
|---|
| Q4 2014 | QURE
UNIQURE | | SHS | 32,000 | 0 | -32,000 | $296,000 | $0 | -$296,000 | 2015-02-17 |
|---|
| Q4 2014 | RVP
RETRACTABLE TECHNOLOGIES INC | United States | COM | 20,000 | 0 | -20,000 | $58,000 | $0 | -$58,000 | 2015-02-17 |
|---|
| Q3 2014 | ARDX
ARDELYX INC | United States | COM | 25,000 | 0 | -25,000 | $399,000 | $0 | -$399,000 | 2014-11-14 |
|---|
| Q1 2014 | TGTX
TG THERAPEUTICS INC | United States | COM | 75,000 | 0 | -75,000 | $293,000 | $0 | -$293,000 | 2014-05-15 |
|---|
| Q3 2013 | INFU
INFUSYSTEM HOLDINGS INC | United States | COM | 474,484 | 0 | -474,484 | $707,000 | $0 | -$707,000 | 2013-11-14 |
|---|
| Q3 2013 | VRTX
VERTEX PHARMACEUTICALS INC | United States | COM | 8,600 | 0 | -8,600 | $689,000 | $0 | -$689,000 | 2013-11-14 |
|---|